To include your compound in the COVID-19 Resource Center, submit it here.

Heron’s HTX-011 meets postoperative pain endpoints

Heron Therapeutics Inc. (NASDAQ:HRTX) gained $5.80 (27%) to $27.30 on Monday after it said HTX-011 met the primary and key secondary endpoints

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE